Breaking news

Apple Ordered To Remit $634 Million For Patent Infringement

Apple Inc. now faces a staggering $634 million judgment after a California federal jury found the tech giant infringed on Masimo’s patent regarding blood oxygen monitoring technology.

Landmark Intellectual Property Ruling

The verdict, reported by Reuters, centers on the Apple Watch’s workout and heart rate notification features, which the jury determined unlawfully incorporated Masimo’s patented pulse oximetry innovations. According to Masimo, a leader in medical device technology (Masimo), this legal win is a critical measure to safeguard their technological advancements that directly benefit patient care.

Strategic Implications For Apple

An Apple spokesperson noted plans to appeal the decision, contesting that the patent in question expired in 2022 and dated back to outdated patient monitoring methods. This response underscores a broader debate over legacy technologies versus evolving innovation paradigms.

Broader Context Of The Dispute

The contentious legal battle extends beyond patent infringement alone. Masimo has previously accused Apple of recruiting its talent, including the company’s chief medical officer, to leverage its pulse oximetry expertise. The United States International Trade Commission further bolstered Masimo’s stance in 2023 by banning Apple from importing devices featuring blood oxygen monitoring capabilities—a cautionary precedent that has prompted Apple to re-engineer the function to operate on the paired iPhone rather than the watch.

Counterlitigation And Ongoing Legal Challenges

As the litigation landscape evolves, Masimo is also challenging U.S. Customs and Border Patrol for approving the new Apple Watch imports, while Apple has escalated its contest to higher courts, seeking reversal of the import ban. In a related development, Apple secured a $250 statutory minimum in a countersuit after a jury found Masimo had infringed on its design patents.

This case not only highlights the high stakes involved in protecting intellectual property but also reflects the broader tensions at the intersection of innovation, talent acquisition, and competitive market dynamics in the technology sector.

Eurobank Buys Back €5.9 Million In Shares In One Week

Eurobank S.A. spent €5.88 million repurchasing more than 1.3 million of its own shares on Euronext Athens between August 17 and August 21, 2026.

The purchases are part of the bank’s ongoing share buyback programme, approved by shareholders at the annual general meeting on April 28 and launched following a public announcement on June 10.

More Than 1.3 Million Shares Repurchased

During the five-day trading period, Eurobank bought 1,312,998 shares for a total of €5,882,204.05, at an average price of about €4.48 per share.

The transactions were carried out on Euronext Athens through Eurobank Equities Single Member Investment Firm S.A.

Daily purchases were as follows:

  • August 17: 257,693 shares for €1.16 million, at an average of €4.4951 per share.
  • August 18: 271,616 shares for €1.22 million, averaging €4.4929.
  • August 19: 323,887 shares for €1.44 million, the largest daily purchase, at an average of €4.4336.
  • August 20: 237,344 shares for €1.06 million, averaging €4.4646.
  • August 21: 222,458 shares for €1.01 million, at an average of €4.5305.

Eurobank’s Share Holdings Increase

The buyback programme was formally established through a board resolution adopted on April 29, following shareholder approval and the relevant legal framework.

After the latest purchases, Eurobank holds a total of 22,500,675 of its own shares.

Aretilaw firm
Uol
eCredo
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter